Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

1.425 -1.655 (-53.73%)
Streaming Delayed Price Updated: 12:12 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Which stocks are gapping on Thursday? ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
Which stocks are moving after the closing bell on Wednesday? ↗
Via Chartmill
News headline image
ADC Therapeutics (ADCT) Q4 2025 Earnings Call Transcript ↗
ADC Therapeutics (ADCT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
ADC Therapeutics SA (NYSE:ADCT) Beats Q1 Estimates, But Market Reaction Remains Subdued ↗
Via Chartmill
News headline image
ADCT Q1 2026 Earnings Call Transcript ↗
ADCT Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
ADC Therapeutics SA (NYSE:ADCT) Surges on Q4 2025 Earnings Beat and Pipeline Update ↗
Via Chartmill
Topics Earnings
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview For ADC Therapeutics ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
These stocks are moving in today's session ↗
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Preview: ADC Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Preview: ADC Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Wednesday? ↗
The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
ADC Therapeutics (ADCT) Earnings Call Transcript ↗
ADC Therapeutics (ADCT) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Top 5 Biotech Stocks With Strong Momentum ↗
Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies. 
Via Benzinga
News headline image
A Preview Of ADC Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
ADC Therapeutics's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:TEVA),(NASDAQ:CTOR),(NYSE:ADCT),(NYSE:OSTX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Which stocks are moving on Wednesday? ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Top movers analysis in the middle of the day on 2025-05-14: top gainers and losers in today's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Earnings Scheduled For May 14, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 27, 2025 ↗
 
Via Benzinga
News headline image
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why ↗
Stephens initiates coverage on ADC Therapeutics (ADCT), highlighting Zynlonta's potential in second-line DLBCL and a promising oncology pipeline. Overweight rating, $6 price target. 
Via Benzinga
News headline image
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.